Seminars in Oncology
Volume 33, Issue 1 , Pages 121-138 , February 2006

Vascular Toxicity of Antineoplastic Agents

References 

  1. Bastounis EA , Karayiannakis AJ , Makri GG , et al.   The incidence of occult cancer in patients with deep vein thrombosis (A prospective study) . J Intern Med . 1996;239:153–156
  2. Monreal M , Fernandez-Liamazares J , Perandreu J . Occult cancer in patients with venous thromboembolism (Which patients, which cancer?) . Throm Haemost . 1997;78:1316–1318
  3. Prandorti P , Lensing AWA , Buller HR , et al.   Deep-vein thrombosis and the incidence of subsequent symptomatic cancer . N Engl J Med . 1992;327:1128–1133
  4. Doll DC , Yarbro JW . Vascular toxicity associated with antineoplastic agents . Semin Oncol . 1992;19:580–596
  5. Doll DC , Yarbro JW . Vascular toxicity associated with chemotherapy and hormonotherapy . Curr Opin Oncol . 1994;6:345–350
  6. Wagevoort CA . Pulmonary veno-occlusive disease. Entity or syndrome? . Chest . 1997;69:82–86
  7. Thadany V , Burrow C , Whitaker W , et al.   Pulmonary veno-occlusive disease . Q J Med . 1975;44:133–156
  8. Corrin G , Spencer H , Turner-Warwich M , et al.   Pulmonary veno-occlusion (An immune complex disease?) . Virchows Arch . 1974;364:81–91
  9. Rose AG . Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma . South Afr Med J . 1983;64:636–638
  10. Joselson R , Warnock M . Pulmonary veno-occlusive disease after chemotherapy . Hum Pathol . 1983;13:88–91
  11. Waldhorn RE , Tsou E , Smith FP , et al.   Pulmonary veno-occlusive disease associated with niicroangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma . Med Pediatr Oncol . 1984;12:394–396
  12. Lombard CM , Churg A , Winokur S . Pulmonary veno-occlusive disease following therapy for malignant neoplasms . Chest . 1987;92:871–876
  13. Capewell Sj , Wright Aj , Ellis DA . Pulmonary veno-occlusive disease in association with Hodgkin’s disease . Thorax . 1984;39:554–555
  14. Troussard X , Bemaudin JF , Cordonnier C , et al.   Pulmonary veno-occlusive disease after bone marrow transplantation . Thorax . 1984;39:956–957
  15. Giralt SA , LeMaistre CF , Vriesendorp HM , et al.   Etoposide, cyclophosphamide, total body irradiation, and allogenic bone marrow transplantation for hematologic malignancies . J Clin Oncol . 1990;12:1923–1930
  16. Steward GC , Pellier I , Mahajan A , et al.   Severe pulmonary hypertension (a frequent complication of stem cell transplantation for malignant infantile osteoporosis) . Br J Haematol . 2004;124:63–71
  17. Bruckman C , Linder W , Roos R , et al.   Severe pulmonary vascular occlusive disease following bone marrow transplantation . Eur J Transplant . 1991;150:242–245
  18. Sanderson JE , Spiro SG , Hendry AT , et al.   A case of pulmonary veno-occlusive disease responding to treatment with azathioprine . Thorax . 1977;32:140–148
  19. Zafrani S , Pinaudeau Y , Dhumeaux D . Drug-induced vascular lesions of the liver . Arch Intern Med . 1983;143:495–502
  20. Bras G , Jelliffe DB , Stuart KL . Veno-occlusive disease of liver with non-portal type of cirrhosis occuring in Jamaica . Arch Pathol Lab Med . 1954;57:285–300
  21. Rollins BJ . Hepatic veno-occlusive disease . Am J Med . 1986;81:297–306
  22. Ledwig L , Hashimoto E , McGill DB . Classification of hepatic venous outflow obstruction (ambiguous terminology of the Budd-Chiari syndrome) . Mayo Clin Proc . 1996;65:51–55
  23. Reed GB , Cox AJ . The human liver after radiation injury (A form of veno-occlusive disease) . Am J Pathol . 1966;48:597–611
  24. Brodsky  , Johnson H , KiUmann SA . Fibrosis of central and hepatic veins, and perisinusoidal spaces of the liver following prolonged administration of urethane . 1 Am J Med . 1961;30:976–980
  25. Griner PF , Elbadawi A , Packman CH . Veno-occlusive disease of the liver after chemotherapy of acute leukemia (Report of two cases) . Ann Intern Med . 1976;85:578–582
  26. Gill RA , Onstad GR , Cardamone JM , et al.   Hepatic veno-occlusive disease caused by 6-thiioguanine . Ann Intern Med . 1982;96:58–60
  27. Sloane JP , Farthing NUG , Powles PL . Histopathological changes in the liver after allogeneic bone marrow transplantation . J Clin Pathol . 1980;33:344–348
  28. Woods WG , Dehner LP , Nesbit ME , et al.   Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation . Am J Med . 1980;68:285–290
  29. Burkhardt A , Kloppet G . Unusual obliterative disease of the hepatic veins in an infant . Virchows Arch . 1977;375:225–232
  30. McIntyre RE , Magidson JG , Austin GE , et al.   Fatal veno-occlusive disease of the liver following high-dose 1,3-bis (2-chloroethyl)-l-nitrosourea (BCNU) and autologous bone marrow transplantation . Am J Clin Pathol . 1981;75:614–617
  31. Vassal G , Hartmann  , Benhamon E . Busulfan and veno-occlusive disease of the liver . 0 Ann Intern Med . 1991;112:881; (letter)
  32. Shuhnan HM , McDonald GB , Matthews D , et al.   An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation . Cancer . 1982;79:1178–1191
  33. Lazarus HM , Gottfried MR , Herzig RH , et al.   Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation . Cancer . 1982;49:1789–1795
  34. Gottfried MR , Sudilovsky O . Hepatic veno-occlusive disease after high-dose mitomycin C and autologous bone marrow transplantation therapy . Hum Pathol . 1982;13:646–650
  35. Erichsen C , Jonsson PE . Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma . J Surg Oncol . 1984;27:268–270
  36. Marubbio AT , Danielson B . Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine . Gastroenterology . 1975;69:739–743
  37. Read AE , Wiesner RH , LaBrecque DR , et al.   Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy . Ann Intern Med . 1986;104:651–655
  38. Green DM , Finkelstein JZ , Norkool P , et al.   Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine . Cancer . 1988;62:270–273
  39. Green DM , Norkool P , Breslow NE , et al.   Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules (A report from the National Wilms’ Tumor Study) . J Clin Oncol . 1990;8:1525–1530
  40. Raine J , Bownian A , Wallendszus K , et al.   Hepatopathy-thrombocytopenia syndromes complication of dactinomycin therapy for Wilms’ tumor. A report from the United Kingdom Children’s Cancer Study Group . J Clin Oncol . 1991;9:268–273
  41. Ortega JA , Donaldson SA , Ivy SP , et al.   Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma . Cancer . 1997;79:2435–2439
  42. Hazar V , Kutluk T , Akyuz C , et al.   Veno-occlusive disease-like hepatotoxicity in two children receiving chemotherapy for Wilms’ tumor and clear cell sarcoma of kidney . Pediatr Hematol Oncol . 1998;15:85–89
  43. Cubc S , Kraker J , Kuljis D , et al.   Fatal hepatic veno-occlusive disease with fibrinolysis as the cause of death during preoperative chemotherapy for nephroblastoma . Med Pediatr Oncol . 1998;31:175–176
  44. Dobbie M , Hofer S , Oberholzer R , et al.   Veno-occlusive disease of the liver induced by gemcitabine . Ann Oncol . 1998;9:681; (letter)
  45. Dumontet C , Morschauser F , Solal-Gelginy P , et al.   Gemcitabine as a single agent in the treatment of replased or refractory low grade non-Hodgkin’s lymphoma . Br J Haematol . 2001;113:772–778
  46. Giles FJ , Kantarjian HM , Kornblau SM , et al.   Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation . Cancer . 2001;92:406–413
  47. Kell WJ , Burnett AK , Chopra R , et al.   A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute leukemia . Blood . 2003;102:4277–4283
  48. Rajvanshi P , Shulman HM , Sievers EL , et al.   Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy . Blood . 2002;99:2310–2314
  49. Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation . Blood . 1995;85:3005–3020
  50. McDonald GB , Sharma P , Matthews DE , et al.   Veno-occlusive disease of the liver after bone marrow transplantation (Diagnosis, incidence, and predisposing factors) . Hepatology . 1984;4:116–122
  51. McDonald GB , Hinds MS , Fisher LD , et al.   Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation (A cohort study of 355 patients) . Ann Intern Med . 1993;118:255–267
  52. Essel JH , Thompson JM , Harman GS , et al.   Increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide . Blood . 1992;79:2782–2788
  53. Grochow LB , Jones RJ , Brundett RB , et al.   Pharmacokinetics of busulfan (Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation) . Cancer Chemother Pharmacol . 1989;25:55–61
  54. Faioni E , Krachmalnicoff A , Bearman SI , et al.   Naturally occurring anticoagulants and bone marrow transplantation (plasma protein C predicts the development of venoocclusive disease of the liver) . Blood . 1993;81:3458–3462
  55. Frickhofen N , Wiesneth M , Jainta C , et al.   Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation . Blood . 1994;83:1998–2004
  56. Beschomer WE , Pino J , Boitnott JK , et al.   Pathology of the liver with bone marrow transplantation (Effects of busulfan, carmustine, acute graft-versus- host disease, and cytomegalovirus infection) . Am J Pathol . 1980;99:369–386
  57. Ayash LJ , Hunt M , Antman K , et al.   Thrombocytopenia in veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas . J Clin Oncol . 1990;8:1699–1706
  58. Anscher MS , Peters WP , Reisenbid-der H , et al.   Transforming growth factor P as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer . N Engl J Med . 1993;328:1592–1598
  59. Murase T , Jirtle RL , McDonald GB . Transforming growth factor plasma concentrations in patients with leukemia and lymphoma receiving chemo radiotherapy and marrow transplantation . Blood . 1994;83:2383–2384 (letter)
  60. Gugliotta L , Catani L , Vianelli N , et al.   High plasma levels of tumor necrosis factor-alpha may be predictive of veno-occlusive disease in bone marrow transplantation . Blood . 1994;83:2385–2386 (letter)
  61. Salat C , Holler E , Kolb HJ , et al.   Plasminogen activator inhibitory confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation . Blood . 1997;89:2184–2188
  62. Rio B , Andreu G , Nicod A , et al.   Thrombocytopenia in veno-occlusive disease after bone marrow transplantation or chemotherapy . Blood . 1986;67:1773–1776
  63. Yoshimoto K , Yahushiji K , Ijuin H , et al.   Colour doppler ultrasonography of a segmental branch of the portal vein is useful for early diagnosis and monitoring of the therapeutic course of venoocclusive disease after allogenic haematopoietic stem cell transplantation . Br J Haematol . 2001;115:945–948
  64. Richardson P , Guinan E . The pathology, diagnosis and treatment of hepatic veno-occlusive disease (Current status and novel approaches) . Br J Haematol . 1999;107:485–493
  65. Saviola A , Luppi M , Potenza L , et al.   Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogomicin (Successful treatment with defibrotide) . Br J Haematol . 2003;123:752–753 (letter)
  66. Stoneham S , Lennard L , Coen P , et al.   Veno-occlusive disease in patients in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukemia . Br J Haematol . 2003;123:100–102
  67. Piel B , Vaidya S , Lancaster D , et al.   Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukemia . Br J Haematol . 2004;125:410–411
  68. Blostein MD , Paltiel OB , Thibault A , et al.   A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation . Bone Marrow Transplant . 1992;10:439–443
  69. Bearman SI , Anderson GL , Mori M , et al.   Veno-occlusive disease of the liver (Development of a model for predicting fatal outcome after marrow transplantation) . J Clin Oncol . 1993;11:1729–1736
  70. Eltani M , Trivedi P , Hobbs JR , et al.   Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen . Lancet . 1993;342:518–521
  71. Attal M , Huguet F , Rubie H , et al.   Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin (A prospective, randomized trial) . Blood . 1992;79:2834–2840
  72. Lee JH , Lee KH , Lee JH , et al.   Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogenic bone marrow transplantation in adults conditioned with busulfan and cyclophosphamide . Br J Haematol . 2002;118:1087–1094
  73. Heikinheimo M , Halila R , Fasth A . Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation . Blood . 1994;83:3036–3040
  74. Cahn JY , Flesch M , Brion A , et al.   Prevention of veno-occlusive disease of the liver after bone marrow transplantation (Heparin or no heparin?) . Blood . 1992;80:2149–2150
  75. Bianco JA , Appelbaum FR , Nemunaitis J , et al.   Phase I-II trial of pentoxifyline for the prevention of transplant-related toxicities following bone marrow transplantation . Blood . 1991;78:1205–1211
  76. Clift RA , Bianco JA , Appelbaum FR , et al.   A randomized controlled trial of pentoxifyline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation . Blood . 1993;82:2025–2030
  77. Attal M , Huguet F , Rubie H , et al.   Prevention of regime-related toxicities after bone marrow transplantation by pentoxifyline (A prospective, randomized trial) . Blood . 1993;82:732–736
  78. Bearman  , Shen DD , Hinds MS , et al.   A phase I/II study of prostaglandin El for the prevention of hepatic veno-occlusive disease after bone marrow transplantation . 51 Br J Haematol . 1993;94:727–730
  79. Gluckman E , Jolivet L , Scrobohaci ML , et al.   Use of prostaglandin El for prevention of liver veno-occlusive disease in leukemic patients treated by allogeneic bone marrow transplantation . Br J Haematol . 1990;74:277–281
  80. Essell JH , Schroeder MT , Harrnan GS , et al.   Ursodial prophylaxis against hepatic complications of allogeneic bone marrow transplantation . Ann Intern Med . 1998;128:975–981
  81. Ruutu T , Eriksson B , Remes K , et al.   Urideoxycholic acid for the prevention of hepatic complications in allogenic stem cell transplantation . Blood . 2002;100:1977–1983
  82. Bearman SI , Shuhart MC , Hinds MS , et al.   Recombinant human tissue plasminogen activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation . Blood . 1992;80:2458–2462
  83. Rostic G , Bandini G , Belardinelli A , et al.   Alteptase for hepatic veno-occlusive disease after bone-marrow transplantation . Lancet . 1992;339:1481–1482
  84. Ringden O , Wennberg L , Ericzon BG , et al.   Alteplase for hepatic veno-occlusive disease after bone marrow transplantation . Lancet . 1992;340:546–547
  85. Bearman SI , Lee JL , Baron AE , et al.   Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients . Blood . 1997;89:1501–1506
  86. Harie WD , Stephens LC , Ruby EI , et al.   Antithrombin III treatment of organ dysfunction during bone marrow transplantation (Results of a pilot study) . Blood . 1996;88:458a; (abstr)
  87. Stasser S , McDonald G . Gastrointestinal and hepatic complications . In:  Forman S ,  Blune K ,  Thomas E editor. Haematopoietic Cell Transplantation . Oxford, UK: Blackwell Science; 1999;p. 1–127
  88. Schitt HJ , Tischler HJ , Ringe B , et al.   Allogenic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation (Clinical and immunological considerations) . Bone Marrow Transplant . 1995;16:473–478
  89. Coccheri S , Biago G . Defibrotide . Cardiovasc Drug Rev . 1991;9:172–196
  90. Ulutin ON . Antithrombotic effect and clinical potential of defibrotide . Semin Thromb Hemost . 1993;19:186–191
  91. Chopra R , Eaton JD , Grassi A , et al.   Defibrotide for the treatment of hepatic veno-occlusive disease (Results of European compassionate-use study) . Br J Haematol . 2000;111:1122–1129
  92. Richardson PG , Murakami C , Jin Z , et al.   Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure (Response without significant toxicity in a high risk population and factors predictive of outcome) . Blood . 2002;100:4337–4343
  93. Greenstone MA , Dowd PM , Nfikhailidis DP , et al.   Hepatic vascular lesions associated with dacarbazine treatment . Br Med J . 1981;282:1744–1745
  94. Asbury RF , Rosenthal SN , Descalzi ME , et al.   Hepatic veno-occlusive disease due to DTIC . Cancer . 1980;45:2670–2674
  95. Houghton AN , Shafi N , Rickles FR . Acute hepatic vein thrombosis occurring during therapy for Hodgkin’s disease. A case report . Cancer . 1979;44:2324–2329
  96. Lehrner IM , Enck RE . Hepatic vein thrombosis after chemotherapy for histiocytoma . Ann Intern Med . 1977;88:575–576 (letter)
  97. Wasser JS , Coleman M . Leukemia chemotherapy and centrilobular hepatic necrosis . Ann Intern Med . 1977;86:508–509 (letter)
  98. Krivoy N , Raz R , Carter A , et al.   Reversible hepatic veno-occlusive disease and 6-thioguanine . Ann Intern Med . 1982;96:788; (letter)
  99. Meindok H , Langer B . Liver scan in Budd-Chiari syndrome . J Nucl Med . 1976;17:365–368
  100. Frosch PJ , Czametzki BM , Macher E , et al.   Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma . J Cancer Res Clin Oncol . 1979;95:281–286
  101. Feaux de Lacroix W , Runne U , Hauk H , et al.   Acute liver dystrophy with thrombosis of hepatic veins (A fatal complication of dacarbazine treatment) . Cancer Treat Rep . 1983;67:779–784
  102. Joensuu H , Soderstrom K , Mikkanen V . Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin’s disease. A case report . -0 Cancer . 1986;58:1437–1440
  103. McClay E , Lusch CJ , Mastrangelo MJ . Allergy-induced hepatic toxicity associated with dacarbazine . Cancer Treat Rep . 1987;71:219–220 (letter)
  104. Ceci G , Bella M , Melissani M , et al.   Fatal hepatic vascular toxicity of DTIC (Is it really a rare event?) . Cancer . 1988;61:1988–1991
  105. Sundstrup B . Raynaud’s phenomenon after bleomycin treatment . Med J Aust . 1978;2:266; (letter)
  106. Adoue D , Arlet P . Bleomycin and Raynaud’s phenomenon . Ann Intern Med . 1984;100:770; (letter)
  107. Malcolm D . Bleomycin-induced injury to the hands . J Med Soc N J . 1978;75:314–316
  108. Vogelzang NJ , Bosl GJ , Johnson K , et al.   Raynaud’s phenomenon (A common toxicity after combination chemotherapy for testicular cancer) . Ann Intern Med . 1981;95:288–292
  109. Teutsch C , Lipton A , Harvey HA . Raynaud’s phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular cancer . Cancer Treat Rep . 1977;61:925–926
  110. Rothberg H . Raynaud’s phenomenon after vinblastine-bleomycin chemotherapy . Cancer Treat Rep . 1978;62:569–570 (letter)
  111. Soble AR . Chronic bleomycin-associated Raynaud’s phenomenon . Cancer Treat Rep . 1978;62:570; (letter)
  112. Chemicoff DP , Buiowski RM , Young JR . Raynaud’s phenomenon after bleomycin treatment . Cancer Treat Rep . 1978;62:570–571 (letter)
  113. Schuten ME , Schmidt CG . Raynaud’s phenomenon and cancer chemotherapy . Ann Intern Med . 1982;96:256; (letter)
  114. Paty JG , Ruffner BW . Bleomycin-vinblastine associated Raynaud’s phenomenon . J Rheumatol . 1980;7:927–928 (letter)
  115. Vogelzang NJ . Raynaud’s phenomenon and cancer chemotherapy . Ann Intern Med . 1982;96:256; (letter)
  116. Grau JJ , Grau M , Nfilla A , et al.   Cancer chemotherapy and Raynaud’s phenomenon . Ann Intern Med . 1983;98:258; (letter)
  117. Dunlop PR , Handy PM . Raynaud’s phenomenon and cryoglobulinemia during chemotherapy for testicular cancer . Cancer Treat Rep . 1983;67:317–318 (letter)
  118. Garnick MB , Canellos GP , Richie JP . Treatment and surgical staging of testicular and primary extragonadal germ cell cancer . JAMA . 1983;250:1733–1741
  119. Kukla Lj , Burrows D , Bressler L , et al.   Bleomycin-induced Raynaud’s phenomenon . Arch Dermatol . 1981;117:604; (letter)
  120. Bostrom B , Woods WG , Ramsay NKL , et al.   Cisplatin, vinblastine, and bleomycin (CVP) therapy for relapsed disseminated neuroblastoma . Cancer Treat Rep . 1984;68:1157–1158
  121. Fossa SD , Aass N , Kaalhus O , et al.   Long term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy . Cancer . 1986;58:2600–2605
  122. Stefenelli T , Kuzmits R , Ulrich W , et al.   Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer . Eur Heart J . 1988;9:552–556
  123. Hansen SW , Olsen N . Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer (Measurement of vasoconstrictor response to cold) . J Clin Oncol . 1989;7:940–942
  124. Boyer M , Raghaven D . Intensive late toxicity assessment program for patients treated for metastatic germ cell tumors with cisplatin-containing combination chemotherapy . Proc Am Soc Clin Oncol . 1989;8:142; (abstr 552)
  125. Roth BJ , Greist A , Kubilis PS , et al.   Cisplatin-based combination chemotherapy for disseminated germ cell tumors (Long-term follow-up) . J Clin Oncol . 1988;6:1239–1247
  126. Stoter G , Koopman A , Vendrick CPJ , et al.   Ten-year survival and later sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin . J Clin Oncol . 1989;7:1099–1104
  127. Brada M , Horwich A , Peckham MJ . Treatment of favorable-prognosis non- seminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin . Cancer Treat Rep . 1987;71:655–656
  128. Cohen IS , Mosher MB , O’Keefe EJ , et al.   Cutaneous toxicity of bleomycin therapy . Arch Dermatol . 1973;107:553–555
  129. Von Gunten CF , Roth EL , Von Roenn JHV . Raynaud’s phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin . Cancer . 1993;72:2004–2006
  130. Flomaa L , Pajunen M , Virkkunen P . Raynaud’s phenomenon progressing to gangrene after vincristine and bleomycin therapy . Acta Med Scand . 1984;216:323–326
  131. Fertakos RJ , Mintzer DM . Digital gangrene following chemotherapy for AIDS-related Kaposi’s sarcoma . Am J Med . 1992;93:581–582
  132. Reid TJHI , Lombardo FA , Redmond J , et al.   Digital vasculitis associated with interferon therapy . Am J Med . 1992;92:702–703
  133. Creutzig A , Caspary L , Freund M . The Raynaud’s phenomenon and interferon therapy . Ann Intern Med . 1996;125:423; (letter)
  134. Bachrneyer C , Farge D , Gluckman E , et al.   Raynaud’s phenomenon and digital necrosis induced by interferon-alpha . Br J Dermatol . 1996;135:481–483
  135. Linden D . Severe Raynaud’s phenomenon associated with interferon-beta treatment for multiple sclerosis . Lancet . 1998;352:878–879 (letter)
  136. Goffin E , Angangio R , Shapiro LM , et al.   Digital gangrene following chemotherapy . Am J Med . 1994;96:571; (letter)
  137. van Basten JPA , Hoekstra HJ , van Driel MF , et al.   Sexual dysfunction in non-seminoma testicular cancer patients is related to chemotherapy-induced angiopathy . J Clin Oncol . 1997;15:2442–2448
  138. Bokemeyer C , Berger CC , Kuczyk M , et al.   Evaluation of long-term toxicity after chemotherapy for testicular cancer . J Clin Oncol . 1996;14:2923–2932
  139. Raiser M , Burns C , Hartmann P , et al.   Raynaud’s phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi’s sarcoma . Eur J Clin Microbiol Infect Dis . 1998;117:58–60
  140. Hladunewich M , Sawka C , Fam A , et al.   Raynaud’s phenomenon and digital gangrene as a consequence of treatment for Kaposi’s sarcoma . J Rheumatol . 1997;12:2371–2375
  141. Malamet R , Wise RA , Ettinger WH , et al.   Nifedipine in the treatment of Raynaud’s phenomenon (Evidence for inhibition of platelet activation) . Am J Med . 1985;78:602–608
  142. Rodenheffer RJ , Runner JA , Wigley F , et al.   Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon . N Eng J Med . 1983;308:880–883
  143. Hantel A , Rowinsky EK , Donehower RC . Nifedipine and oncologic Raynaud’s phenomenon . Ann Intern Med . 1988;108:767; (letter)
  144. Mandel EM , Lewinski U , Djaidetti M . Vincristine-induced myocardial infarction . Cancer . 1975;30:1979–1982
  145. Somers G , Abram M , Witter M , et al.   Myocardial infarction (A complication of vincristine treatment?) . Lancet . 1976;2:690; (letter)
  146. Lejonc JL , Vernant JP , Macquin I , et al.   Myocardial infarction following vinblastine treatment . Lancet . 1980;2:692; (letter)
  147. Schuster JP , Jones SE . Myocardial infarction in a 27 year old woman (Possible complication of treatment with VP-16-213 (NSC-141540), mediastinal irradiation, or both) . Cancer Chemother Rep . 1975;59:887–888 (letter)
  148. Aisner J , Van Echo DA , Whitaker M , et al.   A phase I trial of continuous infusion VP-16-213 (etoposide) . Cancer Chemother Pharmacol . 1982;7:157–160
  149. Mortimer JE , Crowley L , Eyre H , et al.   A phase II randomized study comparing sequential and combined intra-arterial cisplatin and radiation therapy for primary brain tumors . Cancer . 1992;69:1220–1793
  150. Ricci JA , Goldstein L . Coronary artery disease in the presence of bleomycin therapy . Cancer Treat Rep . 1982;66:410; (letter)
  151. Vogelzang NJ , Frenning DH , Kennedy BJ . Coronary artery disease after treatment with bleomycin and vinblastine . Cancer Treat Rep . 1980;53:1159–1160 (letter)
  152. Vogelzang NJ , Torkelson JL , Kennedy BJ . Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine and bleomycin . Cancer . 1985;56:2765–2770
  153. Samuels BL , Vogelzang NJ , Kennedy BJ . Severe vascular toxicity associated with vinblastine, bleomycin and cisplatin chemotherapy . Cancer Chemother Pharmacol . 1987;19:253–256
  154. Bodensteiner DC . Fatal coronary artery fibrosis after treatment with bleomycin, vinblastine, and cisplatin . South Med J . 1981;74:898–899
  155. Doll DC , List AF , Greco FA , et al.   Acute arterial ischemic events following cisplatin-based combination chemotherapy for germ cell tumors of the testis . Ann Intern Med . 1986;105:48–51
  156. Talcott JA , Herman TS . Acute ischemic vascular events and cisplatin . Ann Intern Med . 1987;107:121–197 (letter)
  157. Icli F , Karaoguz H , Dincol D , et al.   Severe vascular toxicity associated with cisplatin-based chemotherapy . Cancer . 1993;72:587–593
  158. House KW , Simon SR , Pugh RP . Chemotherapy-induced myocardial infarction in a young man with Hodgkin’s disease . Clin Cardiol . 1992;15:122–125
  159. Rothenberg ML , Meropol NJ , Poplin EA , et al.   Mortality associated with irinotecan plus bolus fluorouracil/leucovorin (Summary findings of an independent panel) . J Clin Oncol . 2001;19:3801–3807
  160. Boiven JF , Hutchinson GB , Lubin JH , et al.   Coronary artery disease mortality in patients treated for Hodgkin’s disease . Cancer . 1992;69:1241–1247
  161. Nichols CR , Roth BJ , Williams SD , et al.   No evidence of acute cardiovascular complications of chemotherapy for testicular cancer (An analysis of the Testicular Cancer Intergroup Study) . J Clin Oncol . 1992;10:760–765
  162. Yancey RS , Talpaz M . Vindesine-associated angina and ECG changes . Cancer Treat Rep . 1982;66:587–588 (letter)
  163. Dexeus F , Logothetis CJ , Samuels ML , et al.   Continuous infusion of vinblastine for advanced hormone refractory prostate cancer . Cancer Treat Rep . 1985;69:885–886
  164. Subar M , Muggia FM . Apparent myocardial ischemia associated with vinblastine administration . Cancer Treat Rep . 1986;70:690–691 (letter)
  165. Tomirotti M , Riundi R , Pulici S , et al.   Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP) . Tumori . 1984;70:235–236
  166. Shachor L , Beker B , Geffen Y , et al.   Acute ECG change during cyclophosphamide infusion in a patient with bronchogenic carcinoma . Cancer Treat Rep . 1985;69:734–735 (letter)
  167. White DA , Schwartzberg LS , Kris MG , et al.   Acute chest pain syndrome during bleomycin infusions . Cancer . 1987;59:1582–1585
  168. Yano S , Shimada K . Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer . Jpn Circ J . 1996;60:185–188
  169. Rodriguez L , Collazos J , Gallardo M , et al.   Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer . Ann Pharmacother . 1995;29:138–139
  170. Leone B , Rabinovitch M , Ferrari CR , et al.   Cardiotoxicity as a result of 5-fluorouracil therapy . Tumori . 1985;71:55–57
  171. Sanani S , Spaulding M , Masud AR , et al.   5-FU cardiotoxicity . Cancer Treat Rep . 1981;65:1123–1125
  172. Labianca R , Beretta G , Clerici M , et al.   Cardiotoxicity of 5-fluorouracil (A study of 1083 patients) . Tumori . 1982;68:505–510
  173. Pottage A , Holt S , Ludgate S , Langlands AO . Fluorouracil cardiotoxicity . Br Med J . 1978;1:547
  174. Freeman N , Costanza M . 5-Fluorouracil associated cardiotoxicity . Cancer . 1988;61:36–45
  175. Gradishar W , Vokes E , Schilsky R , et al.   Vascular events in patients receiving high-dose infusional 5-fluorouracil based chemotherapy (The University of Chicago experience) . Med Pediatr Oncol . 1991;19:8–15
  176. Vorbiof DA . Cardiotoxicity of 5-fluorouracil . South Afr Med J . 1982;61:635–637
  177. Dent RG , McColl L . 5-Fluorouracil and angina . Lancet . 1975;1:347–348 (letter)
  178. Stevenson DL , Mikhaikidis DP , Gillet DS . Cardiotoxicity of 5-fluorouracil . Lancet . 1977;2:406–407 (letter)
  179. Soukop M , MeVie JG , Cahnan KC . 5-Fluorouracil cardiotoxicity . Br Med J . 1978;1:14–22
  180. Kleiman NA , Lehane DE , Geyer E , et al.   Prinzmetal’s angina during 5-fluorouracil chemotherapy . Am J Med . 1987;82:566–568
  181. Gauci T , Zampa G . Cardiotoxicity of 5-FU . Tumori . 1979;65:487–495
  182. Umsawasdi T , Sawamkatata P . Cardiotoxicity of 5-fluorouracil . Cancer Chemother Rep . 1975;59:1051–1053
  183. Oleksowicz L , Bruckner HW . Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers . Am J Med . 1988;85:750–751
  184. Chaudary S , Song SYK , Jaski BE . Profound, yet reversible, heart failure secondary to 5-fluorouracil . Am J Med . 1988;85:454–456
  185. Collins C , Weiden PL . Cardiotoxicity of 5-fluorouracil . Cancer Treat Rep . 1987;71:733–736
  186. Rezkalla S , Kloner RA , Ensley J , et al.   Continuous ambulatory ECG monitoring during fluorouracil therapy (A prospective study) . J Clin Oncol . 1989;7:509–514
  187. Patel B , Kloner RA , Ensley J , et al.   5-Fluorouracil cardiotoxicity (Left ventricular dysfunction and effects of coronary dilators) . Am J Med Sci . 1987;294:238–243
  188. Jakubowski AA , Kemeny N . Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil . Cancer . 1988;62:266–269
  189. Robben NC , Pippas AW , Moore JO . The syndrome of 5-fluorouracil cardiotoxicity (an elusive cardiomyopathy) . Cancer . 1993;71:493–509
  190. Schooben C , Papageorgiou E , Harstick A , et al.   Cardiotoxicity of 5-fluorouracil in combination with foiling acid in patients with gastrointestinal cancer . Cancer . 1993;72:2242–2247
  191. De Fond M , Makt-Martino MC , Jaillais P , et al.   Cardiotoxicity of high dose continuous infusion fluorouracil (A prospective clinical study) . J Clin Oncol . 1992;10:1795–1801
  192. Anderson NM , Lokich JJ , Moore C . The syndrome of 5-fluorouracil cardiotoxicity (an elusive cardiomyopathy) . Cancer . 1993;72: 9787-2288
  193. Forastiere AA , Metch B , Schuller DE , et al.   Comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck (A Southwest Oncology Group Study) . J Clin Oncol . 1992;10:1245–1251
  194. Saif MW , Szabo E , Grem J , et al.   The clinical syndrome of 5-fluorouracil cardiotoxicity . Proc Am Soc Clin Oncol . 2001;20:404a; (abstr 1613)
  195. Pizzolato JF , Baum M , Steingart RM , et al.   Cardiac toxicity of 5FU (does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience) . Proc Am Soc Clin Oncol . 2004;22:755s; (abstr)
  196. Meinardi MT , Gietema JA , van der Graaf WTA , et al.   Cardiovascular morbidity in long term survivors of metastatic testicular cancer . J Clin Oncol . 2000;18:1725–1732
  197. Huddart RA , Norman A , Shahidi M , et al.   Cardiovascular disease as a long-term complication of treatment for testicular cancer . J Clin Oncol . 2003;21:1513–1523
  198. Murgo AJ . Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents . Semin Hematol . 1987;24:161–177
  199. Gulati SC , Sordiu P , Kernpin S , et al.   Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouraril . Cancer . 1980;45:2252–2257
  200. Hanna WT , Krauss S , Regester RF , et al.   Renal disease after mitomycin C therapy . Cancer . 1981;48:2583–2588
  201. Harden E , Lucas VS , Proia A , et al.   Hemolytic uremic syndrome during therapy with mitomycin C (MMC) plus 5-fluorouracil (5-FU) . Proc Am Soc Clin Oncol . 1982;1:93; (abstr C-360)
  202. Home MK , Cooper B . Microangiopathic hemolytic anemia with metastatic adenocarcinonia (Response to chemotherapy) . South Med J . 1982;75:503–504
  203. Jones BG , Newman CE , Fielding JW , et al.   Intravascular hemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin C . Lancet . 1980;1:1275–1277
  204. Karlin DA , Stroehlein JR . Rash, nephritis, hypertension, and hemolysis in patients on 5-fluorouracil, doxorubicin, and mitomycin C . Lancet . 1980;2:534–535 (letter)
  205. Krauss S , Sonoda T , Solomon A . Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C . Cancer . 1974;1598–1603
  206. Kressel BR , Ryan KP , Kuong AT , et al.   Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma . Cancer . 1981;48:1734–1745
  207. Laffay DL , Tubbs RR , Valenzuela R , et al.   Chronic glomerular microangiopathy and metastatic carcinoma . Hum Pathol . 1979;10:433–438
  208. Lempert KD . Hemolysis and renal impairment syndrome in patients on 5- fluorouracil and mitomycin C . Lancet . 1980;2:369–370 (letter)
  209. Pavy ME , Wiley EL , Abeloff MD . Hemolytic uremic syndrome associated with mitomycin therapy . Cancer Treat Rep . 1982;66:457–461
  210. Rabadi SJ , Khandekar JD , Miller HJ . Mitomycin-induced hemolytic uremic syndrome (Case presentation and review of the literature) . Cancer Treat Rep . 1982;66:1244–1247
  211. Rump KW , Rieger J , Landkisch PG , et al.   Mitomycin-induced hemolysis and renal failure . Lancet . 1980;2:1037–1038 (letter)
  212. Bruntsch U , Froos G , Tigges F , et al.   Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients . Eur J Clin Oncol . 1984;20:905–909
  213. Zimmerman S , Smith FF , Phillips TM , et al.   Gastric carcinoma and thrombotic thrombocytopenic purpura (Association with plasma immune complex concentration) . Br Med J . 1982;284:1432–1434
  214. Perry DJ . Reversible microangiopathic hemolytic anemia after mitomycin C . Cancer Chemother Pharmacol . 1983;10:223
  215. Lyman NW , Michaelson R , Viscuso RL , et al.   Mitomycin-induced hemolytic uremic syndrome. Successful treatment with corticosteroids and intense plasma exchange . Arch Intern Med . 1983;143:1617–1618
  216. Grocker J , Jones EL . Hemolytic-uremic syndrome complicating long-term mitomycin C and 5-fluorouracfl therapy for gastric carcinoma . J Clin Pathol . 1983;36:24–29
  217. Cantrell JE , Phillips TM , Schein PS . Carcinoma-associated hemolytic-uremic syndrome (A complication of mitomycin C chemotherapy) . J Clin Oncol . 1985;3:723–734
  218. Jolivet J , Giroux L , Laurin S , et al.   Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema (A chemotherapy induced syndrome) . Cancer Treat Rep . 1983;67:429–434
  219. Tanriock IF . Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract . Cancer Treat Rep . 1983;61:503–504
  220. Fielding JWL , Fagg SL , Jones BG , et al.   An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer (British Stomach Cancer Group) . World J Surg . 1983;7:390–399
  221. Laufnian L , Courter S , Iritchard J . Fatal mitomycin C (MMC) syndrome heralded by pulmonary symptoms . Proc Am Soc Clin Oncol . 1983;2:197; (abstr 768)
  222. Ravikurnar FS , Sibley R , Reed K , et al.   Renal toxicity of mitomycin C . Am J Clin Oncol . 1984;7:279–285
  223. Loprinzi CL . Mitomycin C-induced pulmonary and renal toxicities . Wis Med J . 1984;83:16–17
  224. Ito S , Hirono S . Two cases of microangiopathic hemolytic anemia caused by anticancer drugs which showed rapid improvement after administration of aspirin and dipyridamole . Rinsho Ketsueki . 1982;23:730–735
  225. Jao W , Manaligod JR . Renal disease associated with mitomycin therapy . Ultrastruct Pathol . 1983;5:83–88
  226. Boven E , Findeo IM . Mitomycin C. Interstitial pneumonitis and hemolytic uraemic syndrome . Neth J Med . 1983;26:153–156
  227. Khojasteh A , Reynolds RD , Garcia AR , et al.   Hemolytic uremic-like syndrome following a single dose of mitomycin C . Proc Am Soc Clin Oncol . 1984;3:4; (abstr 16)
  228. Van Speeuwel JP , Hemrika MH , Dammaat CEM , et al.   Letter to the editor . Neth J Med . 1983;26:287–288 (letter)
  229. Peterson KB , Smith WE . Mitomycin induced hemolytic uremic syndrome . Samaritan Med . 1984;2:17–20
  230. Simon P , Herve JP , Ramee MP , et al.   La nephrotoxicite de la mitomycin C. Trois nouvelles observations et revue de la litterature . Nephrologie . 1982;3:152–157
  231. Willie GR , Levy SM , Michaels RE , et al.   Hemolytic uremic syndrome in a patient receiving mitomycin C and 5-fluorouracil . Henry Ford Hosp Med J . 1983;31:104–109
  232. Valavaara R , Nordman E . Renal complications of mitomycin C therapy with special references to the total dose . Cancer . 1985;55:47–50
  233. Hug V , Burgess A , Blumenschein G , et al.   Effect of cyclophosphamide on the mitomycin-based syndrome of thrombotic thrombocytopenic purpura . Cancer Treat Rep . 1985;69:565–566 (letter)
  234. Price TM , Murge AJ , Keveney JJ , et al.   Renal failure and hemolytic anemia associated with mitomycin C (A case report) . Cancer . 1985;55:51–56
  235. Verwey J , Boven E , Van Der Muelen J , et al.   Recovery from mitomycin C induced hemolytic uremic syndrome (A case report) . Cancer . 1984;54:2878–2881
  236. Garibotto G , Acquarone N , Saffloti S , et al.   Successful treatment of mitomycin-C associated hemolytic uremic syndrome by plasmapheresis . Nephron . 1989;51:409–412
  237. Fields SM , Lindley CM . Thrombotic n-microangiopathy associated with chemotherapy (A case report and review of the literature) . DICP . 1989;23:582–588
  238. Sheldon R , Slaughter D . A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma . Cancer . 1986;58:1428–1436
  239. Hostetter AL , Tubbs RR , Ziegler T , et al.   Chronic glomerular microangiopathy complicating metastatic carcinoma . Hum Pathol . 1987;18:342–348
  240. Verwey J , Vries JD , Pinedo HM . Mitomycin C induced renal toxicity, a dose dependent side effect? . Eur J Cancer Clin Oncol . 1987;23:195–199
  241. Mergenthaler HG , Binsack T , Wilmanns W . Carcinoma associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-Adriamycin-mitomycin C combination chemotherapy . Oncology . 1988;45:11–14
  242. McCarthy JT , Staats BA . Pulmonary hypertension, hemolytic anemia, and renal failure (A mitomycin associated syndrome) . Chest . 1986;89:608–611
  243. Lessesne JB , Rothschild N , Erickson B , et al.   Cancer associated hemolytic uremic syndrome (Analysis of 85 cases from a national registry) . J Clin Oncol . 1989;7:781–789
  244. Liu KM , Mittelman A , Sproul EE , et al.   Renal toxicity in man treated with mitomycin C . Cancer . 1971;28:1314–1320
  245. Weiss RB , Poster DS . The renal toxicity of cancer chemotherapeutic agents . Cancer Treat Rev . 1982;9:37–56
  246. Haur RW , Verani R , Weirunan EJ . Mitomycin associated renal failure. Case report and review . Arch Intern Med . 1983;143:803–807
  247. Morel-Maroger L . Nephrology forum (Adult hemolytic uremic syndrome) . Kidney Int . 1980;18:125–134
  248. Agnelli G , Gresele P , Nenci GG . Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin C treatment . Cancer Chemother Pharmacol . 1981;5:205–206 (letter)
  249. Chow S , Roscoe J , Cattran DC . Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome to mitomycin . Am J Kidney Dis . 1986;7:407–412
  250. Grem JL , Merritt JA , Carbone PP . Treatment of mitomycin associated microangiopathic hemolytic anemia with vincristine . Arch Intern Med . 1986;46:566–568
  251. Zimmerman SE , Smith FF , Phillips TM , et al.   Gastric carcinoma and thrombotic thrombocytopenic purpura (Association with plasma immune complex concentrations) . Br Med J . 1982;284:1432–1434
  252. Korec  , Schein PS , Smith FP . Treatment of cancer associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion . 5 J Clin Oncol . 1986;4:210–215
  253. Snyder HW , Mittleman A , Oral A , et al.   Treatment of cancer chemotherapy associated thrombocytopenia purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma . Cancer . 1993;71:1882–1892
  254. Licciardello J , Moake J , Rudy C . Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy . Oncology . 1985;42:296–300
  255. Jackson AM , Rose BD , Graff LG , et al.   Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy . Ann Intern Med . 1984;101:41–44
  256. Desablens B , Fievet P , Pruna A , et al.   Hemolytic-uremic syndrome after cancer chemotherapy without mitomycin C . Nephron . 1986;42:340–344
  257. Van De Meer J , De Vries EGE , Vriesendorp R , et al.   Hemolytic uremic syndrome in a patient on cisplatin, vinblastine, and bleomycin . J Cancer Res Clin Oncol . 1985;110:119–122
  258. Gradishar WJ , Vokes EE , Mi K , et al.   Chemotherapy related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report . Cancer . 1990;66:1914–1918
  259. Watson PR , Guthrie TH , Caruana RJ . Cisplatin-associated hemolytic uremic syndrome (Successful treatment with staphylococcal protein A column) . Cancer . 1989;64:1400–1403
  260. Coates AS , Childs A , Cox K , et al.   Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron . Ann Oncol . 1992;3:773–774
  261. van der Heijden M , Ackland SP , Deveridge S . Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy (A case report and review of the literature) . Acta Oncol . 1998;37:107–109
  262. Walker RW , Rosenblum MK , Kempin SJ , et al.   Carboplatin-associated thrombotic microangiopathic hemolytic anemia . Cancer . 1989;64:1017–1020
  263. Case records MGH. Case 16-1988 . N Engl J Med . 1988;318:1047–1057
  264. Carey RW , Harris N . Thrombotic microangiopathy in three patients with cured lymphoma . Cancer . 1989;63:1393–1397
  265. Byrnes JJ , Baquerizo H , Gonzalez M , et al.   Thrombotic thrombocytopenic purpura subsequent to acute myelogenous chemotherapy . Am J Hematol . 1986;21:299–304
  266. Leach JW , Pham T , Diamandidis D , et al.   Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following treatment with deoxyforcomycin in a patient with cutaneous T-cell lymphoma (A case report) . Am J Hem . 1999;61:268–270
  267. Fung MC , Storniolo AM , Nguyen B , et al.   A review of hemolytic uremic syndrome in patients with gemcitabine therapy . Cancer . 1999;85:2023–2032
  268. Harris DCH , Lawrence S , Bradstock KF , et al.   Intraglomerular thrombosis with deoxycoformycin-reversible acute renal failure . Clin Nephrol . 1984;21:194–196
  269. Sakai C , Takagi T , Wakatsuki S , et al.   Hemolytic uremic syndrome due to deoxycoformycin (A report of the second case) . Intern Med . 1995;34:593–596
  270. Honda K , Ando A , Endo M , et al.   Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia . Am J Kidney Dis . 1997;30:123–130
  271. Fisher DC , Sherrill GB , Hussein A , et al.   Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer . Bone Marrow Transplant . 1996;18:193–198
  272. Pettitt AR , Clark RE . Thrombotic microangiopathy following bone marrow transplantation . Bone Marrow Transplant . 1994;14:495–504
  273. Moake JL , Byrnes JJ . Thrombotic microangiopathies associated with drugs and bone marrow transplantation . Hematol Oncol Clin North Am . 1996;10:485–497
  274. Rabinowe SN , Soiffer RJ , Tarbell NJ , et al.   Hemolytic uremic syndrome following bone marrow transplantation in adults for hematologic malignancies . Blood . 1991;77:1837–1844
  275. Fuge R , Bird JM , Fraser A , et al.   The Clinical features, risk factors and outcome of thrombotic thrombocytopenia purpura occurring after bone marrow transplantation . Br J Haematol . 2001;113:59–64
  276. Ojik HV , Biesma DH , Fijhnheer R , et al.   Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation . Br J Haematol . 1997;96:641–643
  277. Sack GH , Levin J , Bell WR . rousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms (Clinical, pathophysiologic and therapeutic features) . Medicine . 1997;56:1–37
  278. Kukla LJ , McGuire WP , Lad T , et al.   Acute vascular episode associated with therapy for carcinoma of the upper aerodigestive tract with bleomycin, vincristine, and cisplatin . Cancer Treat Rep . 1982;66:369–370
  279. Fallon B , Clark J , Frei E . Vascular complications during cisplatin-bleomycin-methotrexate and cisplatin 5-FU in induction chemotherapy for advanced stage III and IV squamous cell carcinoma of the head and neck . Proc Am Soc Clin Oncol . 1986;5:134; (abstr 521)
  280. Allerton R . Acute mesenteric ischemia associated with 5-FU, cisplatin and vincristine chemotherapy . Clin Oncol . 1996;8:116–117
  281. Cantwell BMJ , Manniz KA , Roberts JT , et al.   Thromboembolic events during combination chemotherapy for germ cell malignancy . Lancet . 1988;2:1086–1087 (letter)
  282. Hall MR , Richards MA , Harper PG . Thromboembolic events during combination chemotherapy for germ cell malignancy . Lancet . 1986;2:1259; (letter)
  283. Lederman GS , Garnick MB . Pulmonary emboli as a complication of germ cell cancer treatment . J Urol . 1987;137:1236–1237
  284. Czaykowski PM , Moore M , Tannock IF . High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy . J Urol . 1998;160:2021–2024
  285. Garsft IWH , Cooper GG , Hood JM . Arterial thrombosis after treatment with bleomycin and cisplatin . Br Med J . 1990;300:10–18 (letter)
  286. Molloy RG , Welch GC , Drury JK , et al.   Arterial thrombosis after chemotherapy with cisplatin, vinblastine and methotrexate . Br J Clin Pract . 1995;49:50–51
  287. Lepidini G , Biancari F , D’Andma V . Severe thrombosis after chemotherapy for metastatic adenocarcinorna of the testis maintaining complete remission for a long period . Scand J Urol Nephrol . 1996;31:221–299
  288. Seiffer EJ , Young RC , Longo DL . Deep venous thrombosis during therapy for Hodgkin’s disease . Cancer Treat Rep . 1985;69:1011–1013
  289. Clarke CS , Otridge BW , Carney DN . Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin’s lymphoma . Cancer . 1990;66:2027–2030
  290. Cantwell BMJ , Carmichael J , Ghani SE , et al.   Thromboses and thrombolic in patients with lymphoma during cytotoxic chemotherapy . Br Med J . 1988;2:179–180
  291. Miller TP , Dahlberg S , Weich JK , et al.   Unfavorable histologies of non-Hodgkin’s lymphoma treated with ProMACE-CytaBOM (A groupwide Southwest Oncology Group Study) . J Clin Oncol . 1990;8:1951–1958
  292. Weiss RB , Tormey DC , Holland JF , et al.   Venous thrombosis during multimodality treatment of primary breast carcinoma . Cancer Treat Rep . 1981;65:677–679
  293. Booth BW , Weiss RB . Venous thrombosis during adjuvant chemotherapy . N Engl J Med . 1981;305:168; (letter)
  294. Manni A , Trujillo JE , Pearson OH . Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer (Effects on survival) . Cancer Treat Rep . 1980;64:111–116
  295. Goodnough LT , Saito H , Manni A , et al.   Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients . Cancer . 1984;54:1264–1268
  296. Levine MN , Gent M , Hirsh J , et al.   The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer . N Eng J Med . 1988;318:404–407
  297. Saphner T , Toriney DC , Gray R . Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer . J Clin Oncol . 1991;9:286–294
  298. Fisher B , Redmond C , Wickerham DL , et al.   Doxorubicin-containing regimens for the treatment of stage II breast cancer (The National Surgical Adjuvant Breast and Bowel Project experience) . J Clin Oncol . 1989;7:572–582
  299. Pritchard KI , Pater L , Paul N , et al.   Thromboembolic complications related to chemotherapy in a National Institute of Canada randomized trial for tamoxifen versus tamoxifen plus chemotherapy in postmenopausal women with axillary node positive receptor positive breast cancer . Proc Am Soc Clin Oncol . 1989;8:25; (abstr 92)
  300. Wall JG , Weiss RB , Norton L , et al.   Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma (A Cancer and Leukemia Group B study) . Am J Med . 1989;87:1455–1466
  301. Rivkin SE , Green S , Metch B , et al.   Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients (A Southwest Oncology Group Study) . J Clin Oncol . 1994;12:2078–2085
  302. Theodossiou C , Kroog G , Ettinghausen S , et al.   Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3 . Cancer . 1994;74:2808–2810
  303. Clahsen PC , van De Velde CJH , Julien JP , et al.   Thromboembolic complications after perioperative chemotherapy in women with early breast cancer (A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study) . J Clin Oncol . 1994;12:1266–1271
  304. Levine M , Hirsh J , Gent M , et al.   Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer . Lancet . 1994;343:886–889
  305. Pritchard KI , Paterson AHG , Paul NA , et al.   Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant chemotherapy for women with breast cancer . J Clin Oncol . 1996;14:2731–2737
  306. Shlebak AA , Smith DB . Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and or hormonal therapy . Cancer Chemother Pharmacol . 1997;39:462–466
  307. Chan ATC , Yeo W , Leung WT , et al.   Thrombolic events with paclitaxel . Clin Oncol . 1996;8:133; (letter)
  308. Deshmukh N , Tripathi SP . Thrombosis of tibial arteries in a patient receiving tamoxifen therapy . Cancer . 1995;76:1006–1008
  309. Weitz IC , Israel VK , Liebman HA . Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden . Cancer . 1997;79:2024–2027
  310. Hall MR , Richards MA , Harper PG . Thromboembolic events during combination chemotherapy for germ cell malignancy . Lancet . 1988;2:1259; (letter)
  311. Weijl NI , Rutten MFJ , Zwinderman AH , et al.   Thromboembolic events during chemotherapy for germ cell cancer (A cohort study and review of the literature) . J Clin Oncol . 2000;18:2169–2178
  312. Lynch TJ , Kass F , Kalish LA , et al.   Cisplatin, 5-fluorouracil, and etoposide for advanced non-small lung cancer . Cancer . 1993;71:2953–2957
  313. Mathews J , Goel R , Evans WK , et al.   Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer . Cancer Chemother Pharmacol . 1997;40:19–22
  314. Kasimis BS , Spiers ASD . Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy . Lancet . 1979;1:159; (letter)
  315. Del Prado PF , Meana JA , Carrion JR . Acute cerebrovascular accident after treatment with cisplatin . Acta Oncol . 1992;31:593–595
  316. Gandia D , Spielman M , Kac J , et al.   Cerebrovascular accident associated with chemotherapy for oesophageal carcinoma . Eur J Cancer . 1992;28:245
  317. Sevelda P , Mayerhofer K , Obermain A , et al.   Thrombosis with paclitaxel . Lancet . 1994;343:727; (letter)
  318. Becker JC , Winkler B , Klingert S , et al.   Antiphospholipid syndrome associated with immunotherapy for patients with melanoma . Cancer . 1994;73:1621–1624
  319. Conti JA , Scher M . Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor . Cancer . 1992;70:2699–2702
  320. Antman KS , Griffin JD , Elias A , et al.   Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression . N Engl J Med . 1988;319:593–598
  321. Stephens LC , Haire WD , Pokorny KS , et al.   Granulocyte macrophage colony stimulating factor (High incidence of apheresis catheter thrombosis during stem cell collection) . Bone Marrow Transplant . 1993;11:57–59
  322. Kawachi Y , Watanabe A , Uchida T , et al.   Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony stimulating factor . Br J Haematol . 1996;94:413–416
  323. Stadler WM , Vogelzang NJ , Amato R , et al.   Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cell cancer (A University of Chicago phase II consortium study) . J Clin Oncol . 2000;18:371–375
  324. Zangari M , Siegel E , Barlogie B , et al.   Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide (Implications of therapy) . Blood . 2002;100:1168–1171
  325. Zangari M . Thalidomide and thromboembolism . Blood . 2002;99:4249; (letter)
  326. Steurer M , Sudmeier I , Stauder R , et al.   Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with Darbepoietin-alpha . Br J Haematol . 2003;121:101–103
  327. Desai AA , Vogelzang NJ , Rini BI , et al.   A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma . Cancer . 2002;95:1629–1636
  328. Fisher B , Costantino J , Redmond C , et al.   A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors . N Engl J Med . 1989;320:479–484
  329. Cushman M , Costantino JP , Bovill EG , et al.   Effect of tamoxifen on venous thrombosis risk factors in women without cancer (The Breast Cancer Prevention Trial) . Br J Haematol . 2003;120:109–116
  330. Rutqvist LE , Mattsson A . Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockhohn Breast Cancer Study Group . J Natl Cancer Inst . 1993;85:1398–1406
  331. Issell BF , Crooke ST . Etoposide (VP-16-213) . Cancer Treat Rev . 1979;6:107–124
  332. O’Dwyer PJ , Alonso MT , Leyland-Jones B , et al.   Teniposide (A review of 12 years of experience) . Cancer Treat Rep . 1984;68:1455–1466
  333. Antman KH , Mayer RJ , Frei E . Vascular, hormonal, teratogenic and miscellaneous toxicities of chemotherapeutic agents . In:  Perry MC ,  Yarbro TW editor. Toxicity of Chemotherapy . Philadelphia, PA: Grune & Stratton; 1984;p. 521–538
  334. Buesa JM , Garcia M , Vaile M , et al.   Phase I trial of intermittent high-dose dacarbazine . Cancer Treat Rep . 1984;68:499–504
  335. Henner WD , Peters WP , Eder JP , et al.   Pharmacokinetics and immediate effects of high-dose carmustine in man . Cancer Treat Rep . 1986;70:877–880
  336. Legha SS , Keating M , Picket S , et al.   Phase I clinical investigation of homoharringtonine . Cancer Treat Rep . 1984;68:1085–1091
  337. Neidhart JA , Young DC , Derocher D , et al.   Phase I trial of homoharringtonine . Cancer Treat Rep . 1983;67:801–804
  338. Warnell RP , Coonley CJ , Gee TS . Homoharringtonine (An effective new drug for remission induction in refractory non-lymphoblastic leukemia) . J Clin Oncol . 1985;3:617–621
  339. Carndchael SM , Eagieton L , Ayers CR , et al.   Orthostatic hypotension during vincristine therapy . Arch Intern Med . 1970;126:290–293
  340. DiBella NJ . Vincristine-induced orthostatic hypotension (A prospective clinical study) . Cancer Treat Rep . 1980;64:359–360 (letter)
  341. Kletzel M , Jaffe N . Systemic hypertension (A complication of intra-arterial cis-diammine dichloroplatinum (II) infusion) . Cancer . 1981;47:245–247
  342. Harrell RM , Sibley R , Vogelzang NJ . Renal vascular lesion after chemotherapy with vinblastine, bleomycin, and cisplatin . Am J Med . 1982;73:429–433
  343. Hansen SW , Growth S , Augured G , et al.   Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer . J Clin Oncol . 1988;6:1728–1731
  344. Spinach SD . Procarbazine . Ann Intern Med . 1974;81:795–800
  345. O’Dwyer PI , Weiss RB . Hypersensitivity reactions induced by etoposide . Cancer Treat Rep . 1984;68:959–961
  346. Weiss RB . Hypersensitivity reactions to cancer chemotherapy . In:  Perry MC ,  Yarbro JW editor. Toxicity of Chemotherapy . Philadelphia, PA: Grune & Stratton; 1984;p. 101–123
  347. Kuenen BC , Egdbert LR , Smit EF , et al.   Dose finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors . J Clin Oncol . 2002;20:1657–1667
  348. Kampmann KK , Graves T , Rogers SD . Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions . Cancer . 1989;63:2482–2485
  349. Burgdorf WC , Gilmore WA , Canick RG . Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia . Ann Intern Med . 1982;97:61–62
  350. Baer MR , King LE , Wolff SN . Palmer-plantar erythrodysesthesia and cytarabine . Ann Intern Med . 1985;102:556; (letter)
  351. Comonnier C , Roujeau JC , Vernant JP , et al.   Cancer chemotherapy and acral erythema . Ann Intern Med . 1982;97:785; (letter)
  352. Silver FS , Espinoza LR , Hartmann RC . Acral erythema and hydroxyurea . Ann Intern Med . 1983;98:675; (letter)
  353. Lokich JJ , Moore C . Chemotherapy-associated palmer-plantar erythrodysesthesia syndrome . Ann Intern Med . 1984;101:798–799
  354. Feldman LD , Ajani JA . Fluorouracil-associated dermatitis of the hands and feet . JAMA . 1985;254:34–79
  355. Curtan CF , Luce JF . Fluorouracil and palmar-plantar erythrodysesthesia . Ann Intern Med . 1989;111:858; (letter)
  356. Vukelja SJ , Lanbando FA , James WD , et al.   Pyridoxine for the palmar-plantar erythrodysesthesia syndrome . Ann Intern Med . 1989;111:688–689 (letter)
  357. Bellmunt J , Mavarno M , Hidalgo R , et al.   Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil . Tumori . 1988;74:329–331
  358. Chiara S , Nobile MT , Barzacchi C , et al.   Hand-foot syndrome induced by high dose, short-term, continuous 5-tluorouracil infusion . Eur J Cancer . 1997;33:967–969
  359. Lurlo A , Fornier M , Caldiera S , et al.   Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy—An underestimated toxic event? . Acta Oncol . 1997;36:653–654
  360. Doyle LA , Berg C , Bottino G , et al.   Erythema and desquamation after high-dose methotrexate . Ann Intern Med . 1983;98:611–612
  361. Cox GJ , Robertson DB . Toxic erythema of palms and soles associated with high dose mercaptopurine chemotherapy . Arch Dermatol . 1986;199:1413–1414
  362. Murphy CP , Harden EA , Herzig RH . Dose related cutaneous toxicities with etoposide . Cancer . 1993;71:153–155
  363. Twelves C , Harper P , Cutsem CV , et al.   A phase III trial of Xeloda (capecitabine) in previously untreated advanced metastatic colorectal cancer . Proc Am Soc Clin Oncol . 1999;18:263a; (abstr 1010)
  364. Conti JA , Kemeny NE , Saltz LB , et al.   Irinotecan is an active agent in untreated patients with metastatic colorectal cancer . J Clin Oncol . 1996;14:709–715
  365. Hoff PM , Valero V , Ibrahim N , et al.   Hand-foot syndrome following prolonged infusion of high doses of vinorelbine . Cancer . 1998;82:965–969
  366. Argila D , Dominguez JD , Iglesias L . Taxol-induced acral erythema . Dermatology . 1996;192: 377-37
  367. Zimmerman GC , Keeling JH . Prevention of docetaxel-induced erythrodysesthesia with local hypothermia . J Natl Cancer Inst . 1994;86:557–558
  368. Vukelia S , Baker WJ , Burris HA . Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere . J Natl Cancer Inst . 1993;1432–1433
  369. Bastida J , Diaz-Cascajo C , Borghi S . Chemotherapy induced acral erythema due to tegafur . Acta Dermatol Venereol . 1997;77:72–73 (letter)
  370. Buceta LR , Buezo GF , Penas PF , et al.   Paimar plantar erythrodysaesthesia syndrome and other cutaneous side effects after treatment with tegafur . Acta Dermatol Venereol . 1997;77:80–81 (letter)
  371. Muggia FM , Hainsworth JD , Jeffers S , et al.   Phase II study of liposomal doxorubicin in refractory ovarian cancer (Antitumor activity and toxicity modification by liposomal encapsulation) . J Clin Oncol . 1997;15:987–993
  372. Burke MC , Bernhard JD , Michelson AD . Chemotherapy induced painful acral erythema in childhood (Burgdorf’s reaction) . Am J Pediatr Hematol . 1989;11:44–45
  373. Demircay Z , Gurbuz O , Alpdogan TB , et al.   Chemotherapy induced acral erythema in leukemic patients (A report of 15 cases) . Int J Dermatol . 1997;36:593–598
  374. Ogawa H , Sugiyama H , Tani Y . High incidence of chemotherapy induced acral erythema in female patients with non-Hodgkin lymphoma treated with the VACOP-B regimen . Leuk Lymphoma . 1997;29:171–177
  375. Patel JS . Pyridoxine for hand-foot syndrome . Pharmacy . 1999;34:604–609
  376. Lauman M , Mortimer J . Effect of pyridoxine on the incidence of palmar plantar erythroderma in patients receiving capecitabine . Proc Am Soc Clin Oncol . 2001;20:392a; (abstr 1565)
  377. Pendharkar D , Goyal H . Novel management of capecitabine induced hand foot syndrome . Proc Am Soc Clin Oncol . 2004;22:755s; (abstr 8105)
  378. Kingsley EC . 5-Fluorouracil dermatitis prophylaxis with a nicotine patch . Ann Intern Med . 1994;120:8135; (letter)
  379. Gibson LE . Cutaneous vasculitis (Approach to diagnosis and systemic associations) . Mayo Clin Proc . 1990;65: 791-229
  380. Paydays S , Zorludemir S , Sahin B . Vasculitis and leukemia . Leuk Lymphoma . 2000;40:105–112
  381. Fonderila CG , Milone GA , Parlovsky S . Cutaneous vasculitis after intermediate dose of methotrexate . Br J Haematol . 1989;72:591–592
  382. Navarro M , Pedragosa R , Lafuerza A , et al.   Leukocytoclastic vasculitis after high dose methotrexate . Ann Intern Med . 1986;105:471–472 (letter)
  383. Marks CR , Willkins RF , Wilske KR , et al.   Small-vessel vasculitis and methotrexate . Ann Intern Med . 1984;100:916; (letter)
  384. Rowinsky EK , McGuire WO , Anhalt GJ , et al.   Hexamethylene bisacetamide induced cutaneous vasculitis . Cancer Treat Rep . 1987;71:471–474
  385. Ahmed I , Chen KR , Nakayama H , et al.   Cytosine arabinoside induced vasculitis . Mayo Clin Proc . 1998;73:239–242
  386. Denefrio JM , Kaplan RS , Eisenberger MA , et al.   Phase II study of cyclophosphamide and cytarabine in the treatment of metastatic adenocarcinoma of the colon and rectum . Cancer Treat Rep . 1981;65:163–164
  387. Bucaloiu ID , Dubagunta S , Pachipala KK , et al.   Fluorouracil related small bowel vasculitis . J Clin Oncol . 2003;21:2441–2442
  388. Voorburg AA , van Beek FT , Slee PH , et al.   Vasculitis due to gemcitabine . Lung Cancer . 2003;37:22; (letter)
  389. Suzuki Y , Tokuda Y , Saitu Y , et al.   Combination of trastuzumab and vinorelbine in metastatic breast cancer . Jpn J Clin Oncol . 2003;33: 524-517
  390. Paydas S , Yavuz S , Disel U , et al.   Vasculitis associated with all trans retinoic acid in a case with acute promyelocytic leukemia . Leuk Lymphoma . 2003;44:547–548
  391. Steinmetz JC , DeConti R , Ginsburg R . Hypersensivity vasculitis associated with 2-deoxycoformycin and allopurinol therapy . Am J Med . 1989;86:499; (letter)
  392. Greenberg HS , Ensminer WE , Seeger JF , et al.   Intraarterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system (A preliminary report) . Cancer Treat Rep . 1981;65:803–810
  393. DeWys WD , Fowler ED . Report of vasculitis and blindness after intra carotid injection of 1,3-bis (2-chloroethyl)-l-nitrosourea (BCNU: NSC-409962) in dogs . Cancer Chemother Rep . 1973;57:33–40
  394. Bernauer W , Gratwohl A , Keller A , et al.   Microvasculopathy in the ocular fundus after bone marrow transplantation . Ann Intern Med . 1991;116:956–957
  395. Wilding G , Caruso R , Lawrence TS , et al.   Retinal toxicity after high-dose cisplatin therapy . J Clin Oncol . 1985;3:1683–1685
  396. Feun LG , Wallace S , Stewart DJ , et al.   Intracarotid infusion of cisdiamminedichloro-platinum in the treatment of recurrent malignant brain tumors . Cancer . 1984;54:794–799
  397. Rankin EM , Pitts JF . Ophthalmic toxicity during carboplatin therapy . Ann Oncol . 1993;4:337–338
  398. Semb KA , Aamdal S , Oan P . Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment . J Clin Oncol . 1998;16:3426–3432
  399. Schwartz RN , Stover L , Dutcher J . Managing toxicities of high-dose interleukin-2 . Oncology . 2002;16:11–20
  400. Pulkkanen K , Kataja V , Johansson R . Systemic capillary syndrome resulting from gemcitabine treatment in renal cell carcinoma (A case report) . J Chemo . 2003;15:287–289
  401. DePas T , Curigliano G , Franceschelli L , et al.   Gemcitabine induced capillary leak syndrome . Ann Oncol . 2001;12:1651–1652
  402. Naubec E , Oberlin O , Belhadj K , et al.   Subcutaneous inflammatory edema induced by MINE chemotherapy . Ann Dermatol . 2001;128:534–537
  403. Lazo JS . Endothelial injury caused by antineoplastic agents . Biochem Pharmacol . 1986;35:1912–1923
  404. Nicholson GL , Custead S . Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity . Cancer Res . 1985;45:331–336
  405. Adamson IYR , Bowden DH . The pathogenesis of bleomycin-induced pulmonary fibrosis in mice . Am J Pathol . 1974;77:185–198
  406. Otsuka K , Murota SL , Mori Y . Stimulatory effect of bleomycin on the hyaluronic acid synthetase in cultured fibroblasts . Biochem Pharmacol . 1978;27:1551–1554
  407. Finch WF , Rodan GP , Buckingham RB , et al.   Bleomycin-induced scleroderma . J Rheumatol . 1980;7:651–659
  408. Mosekey PL , Heniken C , Hunninghake GW . Augmentation of fibroblast proliferation by bleomycin . J Clin Invest . 1986;78:1150–1154
  409. Gould VE , Miller J . Sclerosing alveolitis induced by cyclophosphamide (Ultrastructural observations on alveolar injury and repair) . Am J Pathol . 1975;81:513–530
  410. Cattell V . Mitomycin induced hemolytic uremic kidney (An experimental model in the rat) . Am J Pathol . 1985;121:88–95
  411. Charba D , Moake JL , Harris NIA , et al.   Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies . Am J Hematol . 1993;42:268–277
  412. Furlan M , Robles R , Solenthaler M , et al.   Deficient activity of von Willebrand factor-cleaving protease in chrome relapsing thrombotic thrombocytopenic purpura . Blood . 1997;89:3097–4003
  413. van der Plas RM , Sdiiphorst ME , Huizinga EG , et al.   von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thromocytopenic purpura . Blood . 1999;93:3798–3802
  414. Smith AC , Boyd MR . Effects of BCNU on pulmonary and serum angiotensin converting enzyme activity in rats . Biodiem Pharmacol . 1983;32:3719–3722
  415. Lazo JS . Angiotensin converting enzyme activity in mice after subacute bleomycin administration . Toxicol Appl Pharmacol . 1981;59:395–404
  416. Lerinan A , Hildebrand FL , Margulies KB , et al.   Endothelin. A new cardiovascular regulatory peptide . Mayo Clin Proc . 1990;65:1441–1455
  417. Kanno K , Hirata Y , Emori T , et al.   Endothelin and Raynaud’s phenomenon . Am J Med . 1991;90:130–132
  418. Gobble U , Ebel W , Jurgens H , et al.   Coagulation changes following bleomycin treatment in animals . Proc Am Soc Clin Oncol . 1983;2:39; (abstr 155)
  419. Yen T , Walsh JD , Pejler G , et al.   Cisplatin-induced platelet activation requires mononuclear cells (Role of GMP-140 and modulation of procoagulant activity) . Br J Haematol . 1993;83:259–269
  420. Panella TJ , Peters W , White JG , et al.   Platelets acquire a secretion defect after high dose chemotherapy . Cancer . 1990;65:1711–1716
  421. Ruiz MA , Marugan I , Estelles P , et al.   The influence of chemotherapy on the plasmatic coagulation and fibrinolytic system in lung cancer patients . Thromb Haemost . 1987;158:110; (abstr)
  422. Edwards RL , Klaus M , Matthews E , et al.   Heparin abolishes the chemotherapy induced increase in plasma fibrinopeptide A levels . Am J Med . 1990;89:25–28
  423. Kuzel T , Exparaz B , Green D , et al.   Thrombogenity of intravenous 5-fluorouracil alone or in combination with cisplatin . Cancer . 1990;65:885–889
  424. Canobbio L , Passio T , Ardizzoni A , et al.   Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients . Cancer . 1986;54:1032–1036
  425. Conard L , Horellou MH , Van Dreden P , et al.   Decrease in protein C in L-asparaginase-treated patients . Br J Haematol . 1985;59:725–727 (letter)
  426. Rogers JS , Murgo AF , Fantana JA , et al.   Chemotherapy for breast cancer decreases plasma protein C and protein S . J Clin Oncol . 1988;6:276–281
  427. Feffer SE , Carinosino LS , Fox RL . Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil . Cancer . 1989;63:1303–1307
  428. Gordon BG , Haire WD , Patton DF , et al.   Thrombotic complications of BMT (association with protein C deficiency) . Bone Marrow Transplant . 1993;11:61–65
  429. Rella C , Coviello M , Giotta F , et al.   A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy . Breast Cancer Treat Res . 1996;40:151–159
  430. Enck RE , Rios CN . Tamoxifen treatment of metastatic breast cancer and antithrombin III levels . Cancer . 1984;53:2607–2609
  431. Jordan VC , Fritz NF , Tormey DC . Long term adjuvant therapy with tamoxifen and effects on sex hormone binding globulin and antithrombin III . Cancer Res . 1987;45:4517–4519
  432. Jones AL , Fowles TJ , Trelearen JG , et al.   Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women . Br J Cancer . 1992;66:744–747
  433. Love RR , Surawicz TS , Williams EL . Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy . Arch Intern Med . 1992;152:317–320
  434. Tempelhoff GFV , Dietrich M , Hommel G , et al.   Blood coagulation during adjuvant epirubicin cyclophosphamide chemotherapy in patients with primary operable breast cancer . J Clin Oncol . 1996;14:2560–2568
  435. Bairy O , Cabbay U , Blickstein D , et al.   Levels of protein C and S do not decline subsequent to first line chemotherapy in lymphoma patients . Hematol Oncol . 1997;15:121–127
  436. Jaattela M . Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachexin . Lab Invest . 1991;64:724–742
  437. Bevilacqua ND , Pober JS , Majeau GR , et al.   Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium (Characterization and comparison with the actions of interleukin 1) . Proc Natl Acad Sci USA . 1986;83:4533–4537
  438. Tanaka L , Imamura M , Kasai M , et al.   Rapid analysis of tumor necrosis factor-alpha MRNA expression during veno-occlusive disease of the liver after allogeneic bone marrow transplantation . Transplantation . 1993;55:430–433
  439. Schilsky RL , Anderson T . Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin . Ann Intern Med . 1979;90:929–931
  440. Turiapaty PDNW , Altur BM . Magnesium deficiency produces spasms of coronary arteries (Relationship to etiology of sudden death ischemic heart disease) . Science . 1980;280:198–200
  441. Altura BM , Altura BT , Gebrewold A . Magnesium deficiency and hypertension (Correlation between magnesium-deficient diets and microcirculatory changes in situ) . Science . 1984;223:1315–1317
  442. Rosenfield CS , Broder LE . Cisplatin-induced autonomic neuropathy . Cancer Treat Rep . 1984;68:659–660
  443. Hansen SW . Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer . Br Med J . 1990;300:511–512
  444. Carmichael SM , Eagieton L , Ayers CR , et al.   Orthostatic hypotension during vincristine therapy . Arch Intern Med . 1970;126:290–293
  445. Dibella NJ . Vincristine-induced orthostatic hypotension (A prospective clinical study) . Cancer Treat Rep . 1980;64:359–360
  446. Roca E , Bruera E , Politi PM , et al.   Vinca alkaloid-induced cardiovascular autonomic neuropathy . Cancer Treat Rep . 1985;69:149–151
  447. Hivomen HE , Sahni TT , Heinonen E , et al.   Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy . Cancer . 1989;64:801–805

PII: S0093-7754(05)00436-7

doi: 10.1053/j.seminoncol.2005.11.006

Seminars in Oncology
Volume 33, Issue 1 , Pages 121-138 , February 2006

Article Tools